Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › α-galactosidase A and 1-deoxygalactonojirimycin co-formulation

α-galactosidase A and 1-deoxygalactonojirimycin co-formulation

US Patent 10357548 · Granted Jul 23, 2019

Estimated economic value: $36,490,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

High concentration alpha-glucosidase compositions for the treatment of Pompe dis2025
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2025
Augmented acid alpha-glucosidase for the treatment of Pompe disease2025
Recombinant human acid alpha-glucosidase2025
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2022
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2022
Augmented acid alpha-glucosidase for the treatment of Pompe disease2022
Augmented acid alpha-glucosidase for the treatment of Pompe disease2020
High concentration alpha-glucosidase compositions for the treatment of pompe dis2019
High concentration alpha-glucosidase compositions for the treatment of pompe dis2019
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treat2018
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treat2018